Abstract
Recent evidence suggests that T cells from tumor-bearing patients exhibit abnormalities in signal transduction that render them unresponsive to appropriate activation signals. Here, Karen Zier, Bernd Gansbacher and Silvia Salvadori review evidence that gene therapy with interleukin 2 (IL-2)-secreting tumor-cell vaccines may prevent such signaling defects.
Originalsprache | Englisch |
---|---|
Seiten (von - bis) | 39-45 |
Seitenumfang | 7 |
Fachzeitschrift | Immunology Today |
Jahrgang | 17 |
Ausgabenummer | 1 |
DOIs | |
Publikationsstatus | Veröffentlicht - 1996 |
Extern publiziert | Ja |